Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ConvaTec ( (GB:CTEC) ) has provided an update.
ConvaTec Group PLC has executed a share buyback transaction, purchasing 3,975,464 ordinary shares as part of its ongoing $300 million share buyback program announced in August 2025. This strategic move, facilitated through UBS AG London Branch, is intended to optimize the company’s capital structure and potentially enhance shareholder value by reducing the number of shares in circulation, which may impact the company’s stock price and voting rights.
The most recent analyst rating on (GB:CTEC) stock is a Buy with a £3.25 price target. To see the full list of analyst forecasts on ConvaTec stock, see the GB:CTEC Stock Forecast page.
Spark’s Take on GB:CTEC Stock
According to Spark, TipRanks’ AI Analyst, GB:CTEC is a Outperform.
ConvaTec’s overall stock score is driven primarily by its strong financial performance, characterized by consistent revenue growth and solid profitability. Technical analysis indicates a moderate upward trend, although valuation metrics suggest the stock may be overvalued. The absence of earnings call insights and corporate events limits additional context.
To see Spark’s full report on GB:CTEC stock, click here.
More about ConvaTec
ConvaTec Group PLC operates in the medical products industry, focusing on the development and provision of medical solutions, including wound care, ostomy care, continence, and critical care products. The company serves a global market, aiming to improve the lives of patients with chronic conditions.
Average Trading Volume: 9,421,583
Technical Sentiment Signal: Hold
Current Market Cap: £4.61B
See more insights into CTEC stock on TipRanks’ Stock Analysis page.